Your browser doesn't support javascript.
loading
1H-NMR Plasma Lipoproteins Profile Analysis Reveals Lipid Metabolism Alterations in HER2-Positive Breast Cancer Patients.
Corona, Giuseppe; Di Gregorio, Emanuela; Vignoli, Alessia; Muraro, Elena; Steffan, Agostino; Miolo, Gianmaria.
Afiliação
  • Corona G; Immunopathology and Cancer Biomarkers Unit, IRCCS Centro di Riferimento Oncologico di Aviano (CRO), 33081 Aviano, Italy.
  • Di Gregorio E; Immunopathology and Cancer Biomarkers Unit, IRCCS Centro di Riferimento Oncologico di Aviano (CRO), 33081 Aviano, Italy.
  • Vignoli A; Department of Molecular Science and Nano Systems, Ca' Foscari University of Venice, Via Torino 155, Venezia Mestre, 30172 Venice, Italy.
  • Muraro E; Magnetic Resonance Center (CERM), Department of Chemistry "Ugo Schiff", University of Florence, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Italy.
  • Steffan A; Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine, 50019 Sesto Fiorentino, Italy.
  • Miolo G; Immunopathology and Cancer Biomarkers Unit, IRCCS Centro di Riferimento Oncologico di Aviano (CRO), 33081 Aviano, Italy.
Cancers (Basel) ; 13(22)2021 Nov 21.
Article em En | MEDLINE | ID: mdl-34830999
ABSTRACT
The lipid tumour demand may shape the host metabolism adapting the circulating lipids composition to its growth and progression needs. This study aims to exploit the straightforward 1H-NMR lipoproteins analysis to investigate the alterations of the circulating lipoproteins' fractions in HER2-positive breast cancer and their modulations induced by treatments. The baseline 1H-NMR plasma lipoproteins profiles were measured in 43 HER2-positive breast cancer patients and compared with those of 28 healthy women. In a subset of 32 patients, longitudinal measurements were also performed along neoadjuvant chemotherapy, after surgery, adjuvant treatment, and during the two-year follow-up. Differences between groups were assessed by multivariate PLS-DA and by univariate analyses. The diagnostic power of lipoproteins subfractions was assessed by ROC curve, while lipoproteins time changes along interventions were investigated by ANOVA analysis. The PLS-DA model distinguished HER2-positive breast cancer patients from the control group with a sensitivity of 96.4% and specificity of 90.7%, mainly due to the differential levels of VLDLs subfractions that were significantly higher in the patients' group. Neoadjuvant chemotherapy-induced a significant drop in the HDLs after the first three months of treatment and a specific decrease in the HDL-3 and HDL-4 subfractions were found significantly associated with the pathological complete response achievement. These results indicate that HER2-positive breast cancer is characterized by a significant host lipid mobilization that could be useful for diagnostic purposes. Moreover, the lipoproteins profiles alterations induced by the therapeutic interventions could predict the clinical outcome supporting the application of 1H-NMR lipoproteins profiles analysis for longitudinal monitoring of HER2-positive breast cancer in large clinical studies.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article